Recent advances in the treatment of giant cell arteritis

Area of Science:

• Rheumatology
• Immunology
• Vascular Medicine

Background:

• Giant cell arteritis (GCA) is a systemic, granulomatous, large-vessel vasculitis primarily affecting individuals over 50.
• Cranial manifestations can lead to irreversible blindness, and extra-cranial manifestations may cause significant vascular damage, including stenosis, occlusions, aortitis, aneurysms, and dissections.
• Current glucocorticoid therapy, while effective, is associated with substantial adverse effects and frequent relapses.

Purpose of the Study:

• To review the current understanding of GCA pathogenesis.
• To evaluate the efficacy of tocilizumab as a steroid-sparing therapy.
• To identify unmet needs in GCA management, including patient stratification for adjunctive therapies and long-term treatment strategies.

Main Methods:

• Literature review of GCA pathogenesis and treatment options.
• Analysis of clinical trial data for tocilizumab in GCA.
• Discussion of current therapeutic targets and future research directions.

Main Results:

• Tocilizumab has emerged as an efficacious, steroid-sparing therapy for GCA.
• Ongoing research is exploring additional inflammatory pathways for therapeutic targets.
• Surgical intervention may be necessary for refractory ischemia or aortic complications, but outcomes data are limited.

Conclusions:

• Despite advances, significant unmet needs remain in GCA management.
• Further investigation is required to identify patient subsets benefiting from early adjunctive therapies or long-term immunosuppression.
• The long-term impact of therapies like tocilizumab on vascular complications, such as aortic aneurysms, needs further evaluation.